Company intelligence / Profile preview

89bio

San Francisco, California, United States89bio.com ↗

Ownership: Public · ETNB
Employees: ~85
Development stage: Phase 3

Overview

The company is currently conducting Phase 3 trials for its lead candidate pegozafermin for MASH with advanced fibrosis (including patients with compensated cirrhosis) and SHTG. They have completed enrollment in their Phase 3 ENTRUST trial in SHTG as of February 2025[6].

Therapeutic areas: GastroenterologyCardiovascularMetabolic Disorders
Modalities: FGF21 analog (glycoPEGylated FGF21)
Industry: Biotech

Drug pipeline

1 asset

pegozafermin

Financials

Market cap: $2.2B
Total revenue: $0
Enterprise value: $1.7B

Beyond the preview

Go deeper on 89bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89bio.

Explore the full profile